Allena Pharmaceuticals, Inc. (ALNA): Price and Financial Metrics


Allena Pharmaceuticals, Inc. (ALNA)

Today's Latest Price: $1.23 USD

0.04 (3.36%)

Updated Sep 25 4:00pm

Add ALNA to Watchlist
Sign Up

Overall POWR Rating


POWR Components:

 Trade Grade  Buy & Hold Grade  Peer Grade  Industry Rank


Industry Rank:

Ranked of 233 in Medical - Pharmaceuticals

See all "A" rated Strong Buy stocks

ALNA Daily Price Range
ALNA 52-Week Price Range

ALNA Stock Price Chart Technical Analysis Charts


ALNA Price/Volume Stats

Current price $1.23 52-week high $6.30
Prev. close $1.19 52-week low $0.53
Day low $1.20 Volume 214,154
Day high $1.26 Avg. volume 775,208
50-day MA $1.40 Dividend yield N/A
200-day MA $1.74 Market Cap 46.89M

Allena Pharmaceuticals, Inc. (ALNA) Company Bio


Allena Pharmaceuticals, Inc., a late-stage clinical biopharmaceutical company, engages in developing and commercializing oral enzyme therapeutics to treat patients with rare and severe metabolic, and kidney disorders in the United States. The company’s lead product candidate includes ALLN-177, an oral enzyme therapeutic for the treatment of enteric hyperoxaluria, a metabolic disorder commonly associated with kidney stones in adults. It is also involved in developing ALLN-346 for patients with hyperuricemia and moderate to severe chronic kidney diseases. The company was founded in 2011 and is based in Newton, Massachusetts.


ALNA Latest News Stream


Event/Time News Detail
Loading, please wait...

ALNA Latest Social Stream


Loading social stream, please wait...

View Full ALNA Social Stream

Latest ALNA News From Around the Web

Below are the latest news stories about Allena Pharmaceuticals Inc that investors may wish to consider to help them evaluate ALNA as an investment opportunity.

Allena Pharma advances with its early-stage study for ALLN-346 in hyperuricemia

Allena Pharmaceuticals ([[ALNA]] -1.3%) has dosed the first patient in a Phase 1 trial of ALLN-346, for the treatment of hyperuricemia (elevated levels of uric acid in the blood) in patients with gout and advanced chronic kidney disease ((CKD)).ALLN-346 is an investigational, orally administered, novel urate-degrading enzyme.The Phase 1 study in 24 healthy...

Seeking Alpha | September 8, 2020

Allena Pharmaceuticals Doses First Subject in Phase 1 Clinical Trial of ALLN-346, in Development for the Treatment of Hyperuricemia in Patients with Gout and Advanced Chronic Kidney Disease

Initial Data Expected in the Fourth Quarter of 2020NEWTON, Mass., Sept. 08, 2020 (GLOBE NEWSWIRE) -- Allena Pharmaceuticals, Inc. (NASDAQ:ALNA), a late-stage, biopharmaceutical company dedicated to developing and commercializing first-in-class, oral enzyme therapeutics to treat patients with rare and severe metabolic and kidney disorders, today announced that the first subject has been dosed in a Phase 1 clinical trial of ALLN-346. ALLN-346 is an investigational, orally administered, novel urate-degrading enzyme that has been designed for activity and stability in the gastrointestinal (GI) tract, and is intended for the treatment of hyperuricemia in patients with gout and advanced chronic kidney disease (CKD). Hyperuricemia, or elevated levels of uric acid in the blood, is due to overp...

Yahoo | September 8, 2020

Allena Pharmaceuticals (ALNA) Investor Presentation - Slideshow

The following slide deck was published by Allena Pharmaceuticals, Inc. in conjunction with this event....

SA Transcripts on Seeking Alpha | August 13, 2020

Allena Pharmaceuticals Announces Second Quarter 2020 Financial Results and Provides Business Update

\-- Expanding URIROX-2 Trial Sites; Interim Analysis on Track for the First Quarter of 2022 –- \-- Initiated Phase 1 Clinical Trial of ALLN-346; Initial Data Expected in the Fourth Quarter of 2020 –-\-- Raised Gross Proceeds of $22.7M Through Two Public Offerings, Extending Cash Runway Beyond the Second Quarter of 2021 –-NEWTON, Mass., Aug. 05, 2020 (GLOBE NEWSWIRE) -- Allena Pharmaceuticals (NASDAQ:ALNA), a late-stage, biopharmaceutical company dedicated to developing and commercializing first-in-class, oral enzyme therapeutics to treat patients with rare and severe metabolic and kidney disorders, today reported financial results for the second quarter ended June 30, 2020 and provided a business update.“In concert with our recent financings, our team has moved quickly to i...

Yahoo | August 5, 2020

Allena Pharmaceuticals Increases Previously Announced Bought Deal to $6.7 Million

NEWTON, Mass., July 27, 2020 (GLOBE NEWSWIRE) -- Allena Pharmaceuticals, Inc. (NASDAQ: ALNA), a late-stage, biopharmaceutical company dedicated to developing and commercializing first-in-class, oral enzyme therapeutics to treat patients with rare and severe metabolic and kidney disorders, announced today that, due to demand, the underwriter has agreed to increase the size of the previously announced public offering and purchase on a firm commitment basis 5,125,384 shares of common stock of the Company, at a price to the public of $1.30 per share, less underwriting discounts and commissions. The closing of the offering is expected to occur on or about July 30, 2020, subject to satisfaction of customary closing conditions. H.C. Wainwright & Co. is acting as the sole book-running manager ...

Yahoo | July 28, 2020

Read More 'ALNA' Stories Here

ALNA Price Returns

1-mo -10.22%
3-mo -19.08%
6-mo 27.79%
1-year -69.93%
3-year N/A
5-year N/A
YTD -54.95%
2019 -49.91%
2018 -45.83%
2017 N/A
2016 N/A
2015 N/A

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!



Page generated in 0.6068 seconds.